Brief: Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai)

16/09/2024 12:27

Sept 16 (Reuters) - ImmuneOnco Biopharmaceuticals
Shanghai Inc  1541.HK :
    * INSTIL BIO AND IMMUNEONCO ANNOUNCE GLOBAL REGISTRATIONAL
STRATEGY FOR PD-L1XVEGF BISPECIFIC ANTIBODY, SYN-2510/IMM2510,
IN NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER
    * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510
+
CHEMOTHERAPY COMBINATION IN FIRST-LINE NSCLC ANTICIPATED IN LATE
2024 IN CHINA
    * INSTIL BIO INC - INITIATION OF PHASE 1B/2 IMM2510/SYN-2510
+
CHEMOTHERAPY COMBINATION IN FIRST-LINE TNBC ANTICIPATED IN EARLY
2025 IN CHINA
    * INSTIL BIO INC - US IND SUBMISSION FOR SYN-2510 TARGETED
IN LATE
2024, STARTING WITH PHASE 2 TRIAL OF SYN-2510 MONOTHERAPY IN
SECOND-LINE NSCLC

Source text for Eikon:  ID:nGNX5Mh2y8 
Further company coverage:  1541.HK 

 ((Reuters.Briefs@thomsonreuters.com;))